raremaprare-disease reference indexOrphadata 2026-06-23 · HPO 2026-09-01
ORPHA:537

Toxic epidermal necrolysis

Synonyms: Lyell syndrome

Type
Clinical subtype
Group
Subtype of disorder
Inheritance
Not applicable
Age of onset
All ages
Status
active

An extended form of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum characterized by destruction and detachment of the skin epithelium, involving 30% or more of the body surface area, and mucous membranes. Onset usually occurs 4-28 days after administration of the causal medication and is most frequently associated with anticonvulsants, antibacterial sulfonamides, allopurinol, nevirapine, and oxicams (non-steroidal anti-inflammatory drugs), but many other medications have also been implicated. The disease is not induced by medication in 15% of cases. Histology is characterized by an epidermal necrolysis. Multiple disabling long-term sequelae (especially cutaneous, ocular and psychological) are frequent.

1

Names in Orphadata languages

12 of 12 languages
LangNameSynonyms
enToxic epidermal necrolysisLyell syndrome
frNécrolyse épidermique toxiqueNET · Syndrome de Lyell
deToxische epidermale NekrolyseLyell-Syndrom
esNecrólisis epidérmica tóxicaSíndrome de Lyell
itSindrome di Lyell
nlToxische epidermale necrolyseSyndroom van Lyell
ptNecrólise epidérmica tóxicaSíndrome Lyell
plZespół LyellaToksyczna nekroliza naskórka
csLyellův syndrom= en
ukТоксичний епідермальний некролізСиндром Лайєлла
zh中毒性表皮坏死松解症Lyell综合征
trToksik epidermal nekrolizLyell sendromu

Definition in:

2

Cross-references

qualifier = Orphanet mapping relation
SourceCodeQualifierICD relationValidation
ICD-10L51.2NTBTinclusionvalidated
ICD-11EB13.1Especificvalidated
MONDO0018890Evalidated
UMLSC0014518Evalidated
MedDRA10044223Evalidated

E exact · NTBT this ORPHAcode is narrower than the target · BTNT broader than the target · ND not decided.

3

Classification

Preferential parent (Orphanet linearisation):

Parents in the classifications (1):

No children.

4

Genes

0 direct

Orphanet records no gene directly on this code.

5

Prevalence and incidence

1 record
TypeClassValueAreaQualificationValidationSource
Point prevalenceUnknown—WorldwideClass onlyValidatedORPHANET

Value is Orphadata's ValMoy: the mean estimate per 100 000 for prevalence and incidence, the number of cases or families for case reports.

6

HPO phenotypes

39 annotations · validated 2018-01-29
HPOTerm (as annotated by Orphanet)Diagnostic
Very frequent (99-80%)
HP:0008066Abnormal blistering of the skin
HP:0100792Acantholysis
HP:0001875Decreased total neutrophil count
HP:0002015Dysphagia
HP:0010783Erythema
HP:0012378Fatigue
HP:0012733Macule
HP:0001959Polydipsia
HP:0100806Sepsis
HP:0001873Thrombocytopenia
HP:0001824Weight loss
Frequent (79-30%)
HP:0002027Abdominal pain
HP:0001903Anemia
HP:0012735Cough
HP:0100518Dysuria
HP:0002910Elevated circulating hepatic transaminase concentration
HP:0003781Excessive salivation
HP:0002024Malabsorption
HP:0002205Recurrent respiratory infections
Occasional (29-5%)
HP:0001637Abnormal myocardium morphology
HP:0002103Abnormality of the pleura
HP:0000795Abnormality of the urethra
HP:0000142Abnormality of the vagina
HP:0006554Acute hepatic failure
HP:0000509Conjunctivitis
HP:0200020Corneal erosion
HP:0000621Entropion
HP:0002239Gastrointestinal hemorrhage
HP:0031368Intestinal perforation
HP:0002017Nausea and vomiting
HP:0001733Pancreatitis
HP:0000613Photophobia
HP:0000083Renal insufficiency
HP:0002098Respiratory distress
HP:0002091Restrictive ventilatory defect
HP:0200042Skin ulcer
HP:0001645Sudden cardiac death
HP:0002575Tracheoesophageal fistula
HP:0000572Visual loss

Run the differential on the 11 obligate / very frequent terms

7

Sources for this card